But by night, he runs Gusteau Research Corporation, a one-man shell company he established so he could experiment on his bubbly inoculation: an ingestible polyomavirus vaccine. To make the beer, Buck engineered a special strain of yeast infused with polyomavirus-like particles. Similar particles, delivered via purified insect chitin, have successfully increased antibody levels in rhesus monkeys tested in India, according a 2023 research study published in the journal Vaccine. That had huge implications for inoculation against polyomaviruses, which are mostly found in the urinary track, Buck told Science News. I was reluctant to believe it,” Buck said at the World Vaccine Congress Washington earlier this year.